Matches in Nanopublications for { ?s ?p "[Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_assertion description "[Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245017.RAD4aDQf04G6sYDQVF0hS-JV8h8iWEXSUTnVHFCIA77jc130_provenance.
- NP1245018.RA097oQ5iO27Uo9bwdSgEt5PV1h5QGEnbolHO5jai1OmE130_assertion description "[Studies presented or published during the European Society for Medical Oncology conference demonstrate that combining BRAF and MEK inhibitors improves progression-free and overall survival--and lowers the risk of resistance and toxicities--in patients with metastatic melanoma with BRAF V600E or V600K mutations.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1245018.RA097oQ5iO27Uo9bwdSgEt5PV1h5QGEnbolHO5jai1OmE130_provenance.